Kate Sears
@katesears.bsky.social
Hi I'm Kate, community lead for Medical.watch. Want practice changing updates in oncology/hematology? Get our weekly newsletter and join 2700+ clinicians.
Subscribe for free: Medical.watch
About us: tinyurl.com/Medicalwatch
Subscribe for free: Medical.watch
About us: tinyurl.com/Medicalwatch
Pinned
Kate Sears
@katesears.bsky.social
· Nov 17
Hello #MedSky and #OncSky!
My name's Kate and I'm community lead for Medical.watch, a free newsletter for oncology/hematology professionals.
Our story is here: www.resources.medical.watch/post/why-we-...
I love to post SUPER COOL videos...like this one!
My name's Kate and I'm community lead for Medical.watch, a free newsletter for oncology/hematology professionals.
Our story is here: www.resources.medical.watch/post/why-we-...
I love to post SUPER COOL videos...like this one!
💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
September 19, 2025 at 5:04 PM
💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
Thrilled to see the timely piece
👉 “Precision Oncology and Modernizing Evidence Standards”
🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
🚨 NEJM | Sept 2025
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
www.nejm.org
September 18, 2025 at 4:01 PM
🚨 NEJM | Sept 2025
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)
“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
💫🌟🎓🆕Immune activation & ICI-related fatigue
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
September 17, 2025 at 2:38 PM
💫🌟🎓🆕Immune activation & ICI-related fatigue
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
New study (JHU + Genentech)
✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
🧓👵 Geriatric assessment vs clinical evaluation in MM
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
September 16, 2025 at 4:34 PM
🧓👵 Geriatric assessment vs clinical evaluation in MM
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.
📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
Reposted by Kate Sears
ELEVATE-ing clinical trial reporting in CLL buff.ly/FwUhcEw #hemesky
ELEVATE-ing clinical trial reporting in CLL
In this issue of Blood, Sharman et al1 report on the latest 6-year follow-up of the ELEVATE-TN trial, which previously reported the superiority of acalabru
buff.ly
September 15, 2025 at 5:02 PM
ELEVATE-ing clinical trial reporting in CLL buff.ly/FwUhcEw #hemesky
Reposted by Kate Sears
Breast Cancer in Young Women: When, Why, and How?
Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more:
buff.ly/OB6T5Xs
@loisher.bsky.social
Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more:
buff.ly/OB6T5Xs
@loisher.bsky.social
September 15, 2025 at 5:16 PM
Breast Cancer in Young Women: When, Why, and How?
Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more:
buff.ly/OB6T5Xs
@loisher.bsky.social
Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more:
buff.ly/OB6T5Xs
@loisher.bsky.social
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
September 15, 2025 at 2:36 PM
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
New review (Nat Rev Clin Oncol)
✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies
🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
The treatment landscape for many lymphoma entities continues to evolve rapidly, with
multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following
Clinical Practice Guideli...
www.annalsofoncology.org
September 12, 2025 at 10:41 PM
📑 New ESMO CPG on Lymphomas
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis
www.annalsofoncology.org/article/S092...
Reposted by Kate Sears
Functional synapses between neurons and small cell lung cancer - Nature
Small cell lung cancer cells form functional synapses with glutamatergic neurons, receiving synaptic transmissions and deriving a proliferative advantage from these interactions.
www.nature.com
September 12, 2025 at 2:11 AM
Reposted by Kate Sears
The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors.
In the SunRISe-1 trial: complete responses reported in 82%
ascopost.com/news/septemb...
In the SunRISe-1 trial: complete responses reported in 82%
ascopost.com/news/septemb...
September 11, 2025 at 4:06 PM
The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors.
In the SunRISe-1 trial: complete responses reported in 82%
ascopost.com/news/septemb...
In the SunRISe-1 trial: complete responses reported in 82%
ascopost.com/news/septemb...
Reposted by Kate Sears
🕯️ Today, we pause to remember the lives lost on September 11, 2001, and honor the courage of first responders, survivors, and families whose lives were forever changed.
May we continue to carry forward the lessons of unity, resilience, and compassion.
May we continue to carry forward the lessons of unity, resilience, and compassion.
September 11, 2025 at 5:11 PM
🕯️ Today, we pause to remember the lives lost on September 11, 2001, and honor the courage of first responders, survivors, and families whose lives were forever changed.
May we continue to carry forward the lessons of unity, resilience, and compassion.
May we continue to carry forward the lessons of unity, resilience, and compassion.
🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
September 11, 2025 at 3:14 PM
🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟
✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive
#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch
ascopubs.org/doi/10.1200/...
🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
September 10, 2025 at 9:39 PM
🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)
🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
Reposted by Kate Sears
We are excited to announce the 2026 SITC EU Immuno-Oncology Drug Development Summit. Coming Sept. 2026 in Lausanne, Switzerland. This program will discuss best practices for modern IO drug development & the next wave of IO therapeutics. Join the waitlist: t.co/JhPLTpSvdb 🧪
September 10, 2025 at 4:07 PM
We are excited to announce the 2026 SITC EU Immuno-Oncology Drug Development Summit. Coming Sept. 2026 in Lausanne, Switzerland. This program will discuss best practices for modern IO drug development & the next wave of IO therapeutics. Join the waitlist: t.co/JhPLTpSvdb 🧪
Reposted by Kate Sears
Studying cancer evolution needs multi-region or single cell seq for phylogenetics, right? Amazingly (I think!) we found single-sample bulk methylation suffices, via analysis of "fluctuating methylation". In @nature.com today led by brilliant @calumgabbutt.bsky.social www.nature.com/articles/s41...
Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature
Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.
www.nature.com
September 10, 2025 at 3:21 PM
Studying cancer evolution needs multi-region or single cell seq for phylogenetics, right? Amazingly (I think!) we found single-sample bulk methylation suffices, via analysis of "fluctuating methylation". In @nature.com today led by brilliant @calumgabbutt.bsky.social www.nature.com/articles/s41...
Reposted by Kate Sears
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
ashpublications.org
September 9, 2025 at 8:34 PM
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...
📢 European Journal of Cancer – New Research
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
September 9, 2025 at 4:33 PM
📢 European Journal of Cancer – New Research
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Cost-effectiveness of perioperative Durvalumab + Gem/Cis in MIBC (Germany)
📊 Results:
➡️ Cost: €113,224 (SoC) → €126,386 (+€13,162)
➡️ QALYs: 3.16 → 3.37 (+0.21)
➡️ ICER: €61,006/QALY
➡️ WTP €100,000 → 76.5% probability of cost-effectiveness
Reposted by Kate Sears
The Cancer Planners Forum 2025, hosted by @uiccofficial.bsky.social with @who.int, @iaeaorg.bsky.social, etc held in May 2025 raised urgent global needs for cancer control plans.
Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges
ascopost.com/news/septemb...
Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges
ascopost.com/news/septemb...
September 9, 2025 at 4:12 PM
The Cancer Planners Forum 2025, hosted by @uiccofficial.bsky.social with @who.int, @iaeaorg.bsky.social, etc held in May 2025 raised urgent global needs for cancer control plans.
Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges
ascopost.com/news/septemb...
Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges
ascopost.com/news/septemb...
Reposted by Kate Sears
Manage toxicities associated with bispecific tarlatamab for small cell lung cancer! Learn from a panel of experts during
SITC’s #virtual Advances in Cancer Immunotherapy: A Focus on Lung Cancers program Sept. 12. Learn more: ow.ly/I7HJ50WT8wW 🧪
@drjnaidoo.bsky.social
SITC’s #virtual Advances in Cancer Immunotherapy: A Focus on Lung Cancers program Sept. 12. Learn more: ow.ly/I7HJ50WT8wW 🧪
@drjnaidoo.bsky.social
September 8, 2025 at 3:30 PM
Manage toxicities associated with bispecific tarlatamab for small cell lung cancer! Learn from a panel of experts during
SITC’s #virtual Advances in Cancer Immunotherapy: A Focus on Lung Cancers program Sept. 12. Learn more: ow.ly/I7HJ50WT8wW 🧪
@drjnaidoo.bsky.social
SITC’s #virtual Advances in Cancer Immunotherapy: A Focus on Lung Cancers program Sept. 12. Learn more: ow.ly/I7HJ50WT8wW 🧪
@drjnaidoo.bsky.social
🌍 #MWGlobalOnc
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
September 8, 2025 at 2:55 PM
🌍 #MWGlobalOnc
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
Prognosis & biology of ER-low metastatic breast cancer – TONIC & multicenter cohort
🔑 Key Messages:
✅ ER-low (1–9%) behaves biologically closer to TNBC than ER+/HER2−
✅ Worse OS vs ER+/HER2−; prognosis similar to TNBC
✅ Phenotypic switch from ER+ → ER-low at relapse = poor outcomes
📚 #MWPaperFriday
Geriatric Assessment: ASCO Global Guideline
🔑 Key Messages:
✅ GA identifies vulnerabilities missed by standard oncology evals
✅ Guides treatment tailoring, ↓ toxicity & ↑ QOL in older adults
✅ Universal GA recommended in all ≥65y pts w/ cancer
Geriatric Assessment: ASCO Global Guideline
🔑 Key Messages:
✅ GA identifies vulnerabilities missed by standard oncology evals
✅ Guides treatment tailoring, ↓ toxicity & ↑ QOL in older adults
✅ Universal GA recommended in all ≥65y pts w/ cancer
September 5, 2025 at 8:05 PM
📚 #MWPaperFriday
Geriatric Assessment: ASCO Global Guideline
🔑 Key Messages:
✅ GA identifies vulnerabilities missed by standard oncology evals
✅ Guides treatment tailoring, ↓ toxicity & ↑ QOL in older adults
✅ Universal GA recommended in all ≥65y pts w/ cancer
Geriatric Assessment: ASCO Global Guideline
🔑 Key Messages:
✅ GA identifies vulnerabilities missed by standard oncology evals
✅ Guides treatment tailoring, ↓ toxicity & ↑ QOL in older adults
✅ Universal GA recommended in all ≥65y pts w/ cancer
Reposted by Kate Sears
#SITC25 Science Preview: Join Drs. Michael Lotze @news.upmc.com, Wim Vos, Stephane Champiat @mdanderson.bsky.social, Eric Deutsch @gustaveroussy.fr & Di Dong in the session, “Imaging, Radiomics and Integrated Biomarkers in IO”.
View session details: www.sitcancer.org/2025/schedul...
View session details: www.sitcancer.org/2025/schedul...
September 5, 2025 at 2:37 PM
#SITC25 Science Preview: Join Drs. Michael Lotze @news.upmc.com, Wim Vos, Stephane Champiat @mdanderson.bsky.social, Eric Deutsch @gustaveroussy.fr & Di Dong in the session, “Imaging, Radiomics and Integrated Biomarkers in IO”.
View session details: www.sitcancer.org/2025/schedul...
View session details: www.sitcancer.org/2025/schedul...
Reposted by Kate Sears
Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team
🚨New @ascocancer.bsky.social Guideline Alert! 🌍
Honored to have worked alongside #EnriqueSoto & cols in developing this guideline
Check out the latest recommendations on GA, designed to improve care worldwide
📄Full guideline ascopubs.org/doi/pdf/10.1...
🎙️Don’t miss the accompanying podcast!
Honored to have worked alongside #EnriqueSoto & cols in developing this guideline
Check out the latest recommendations on GA, designed to improve care worldwide
📄Full guideline ascopubs.org/doi/pdf/10.1...
🎙️Don’t miss the accompanying podcast!
September 4, 2025 at 9:14 PM
Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team
Reposted by Kate Sears
MD Anderson researchers developed a new single-cell DNA and RNA sequencing technology to identify ancestral breast cancer cells.
How this can help gain understanding on why some breast cancers are more aggressive than others: spr.ly/6012A8cXg #OncSky #EndCancer
How this can help gain understanding on why some breast cancers are more aggressive than others: spr.ly/6012A8cXg #OncSky #EndCancer
Novel sequencing technology links DNA and RNA to provide molecular insights into breast cancer progression
Novel sequencing technology links DNA and RNA to provide molecular insights into breast cancer progression
spr.ly
September 4, 2025 at 11:00 PM
MD Anderson researchers developed a new single-cell DNA and RNA sequencing technology to identify ancestral breast cancer cells.
How this can help gain understanding on why some breast cancers are more aggressive than others: spr.ly/6012A8cXg #OncSky #EndCancer
How this can help gain understanding on why some breast cancers are more aggressive than others: spr.ly/6012A8cXg #OncSky #EndCancer
Reposted by Kate Sears
New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs
#JITC #ImmunoSky #MedSky
#JITC #ImmunoSky #MedSky
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in h...
bit.ly
September 4, 2025 at 4:16 PM
New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs
#JITC #ImmunoSky #MedSky
#JITC #ImmunoSky #MedSky